Clinical Trials Directory

Trials / Completed

CompletedNCT05098691

Early Onset Preeclampsia and Nectin-4

Serum Nectin-4 Levels in Patients With Early Onset Preeclampsia

Status
Completed
Phase
Study type
Observational
Enrollment
84 (actual)
Sponsor
Hatice Akkaya · Other Government
Sex
Female
Age
18 Years – 40 Years
Healthy volunteers
Not accepted

Summary

Early-onset Preeclampsia (PE) is a pregnancy disorder which may present with adverse pregnancy outcomes. Nectin-4 is an adhesion molecule mainly expressed in placenta. This study aimed to evaluate the relationship between early onset Preeclampsia and serum Nectin 4 levels.

Detailed description

Preeclampsia is assumed as a two-stage disorder arising from defective trophoblast invasion and failure of spiral artery remodeling as the main step responsible for the pathogenesis. PE is classified according to the disease onset time as early-onset PE before 34 weeks and late-onset PE after 34 weeks. Late-onset PE is more commonly seen and accepted as a mild maternal reaction to pregnancy. In early-onset PE, unlike the late-onset, due to the improper placental invasion, the diffuse placental ischemia and the resulting oxidative stress begin at early gestation. Thus, the early-onset PE may result in severe disease leading to perinatal and maternal morbidity and mortality. The nectins are calcium-independent immunoglobulin-like celladhesion molecules and have a pivotal role at cellular junctions, as well as physiological regulations(8). Placenta expressesfor types of nectins; nectin-1, nectin-2, nectin-3, and nectin-4. They are localized at tight junctions and gap junctions of syncitiotrophoblasts(9). Nectin-4 is a relatively novel member of nectin family which has been detected only in placenta and airway epithelium in healthy subjects. Despite, there has been no study published yet to reveal the soluble nectin-4 levels in preeclampsia as well as in early onset disease. In this study, we aimed to investigate the serum nectin-4 levels in early-onset preeclampsia in comparison of the healthy pregnancies.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTserum marker levelstwo groups comparisons

Timeline

Start date
2020-05-01
Primary completion
2020-12-15
Completion
2020-12-30
First posted
2021-10-28
Last updated
2021-10-28

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT05098691. Inclusion in this directory is not an endorsement.